Literature DB >> 22117038

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era.

Andrew M Evens1, Irene Helenowski, Erika Ramsdale, Chadi Nabhan, Reem Karmali, Britt Hanson, Benjamin Parsons, Scott Smith, Annette Larsen, June M McKoy, Borko Jovanovic, Stephanie Gregory, Leo I Gordon, Sonali M Smith.   

Abstract

We investigated a recent (January 1999 to December 2009) cohort of 95 elderly Hodgkin lymphoma subjects. At diagnosis, median age was 67 years (range, 60-89 years), whereas 61% had significant comorbidity, 26% were unfit, 17% had a geriatric syndrome, and 13% had loss of activities of daily living. Overall response rate to therapy was 85%, whereas incidence of bleomycin lung toxicity was 32% (with associated mortality rate, 25%). With 66-month median follow-up, 2-year and 5-year overall survival were 73% and 58%, respectively (advanced-stage, 63% and 46%, respectively). Most International Prognostic Score factors were not prognostic on univariate analyses, whereas Cox multivariate regression identified 2 risk factors associated with inferior overall survival: (1) age more than 70 years (2.24; 95% CI, 1.16-4.33, P = .02) and (2) loss of activities of daily living (2.71; 95% CI, 1.07-6.84, P = .04). Furthermore, a novel survival model based on number of these risk factors (0, 1, or 2) showed differential 2-year OS of 83%, 70%, and 13%, respectively (P < .0001) and 5-year OS of 73%, 51%, and 0%, respectively (P < .0001).

Entities:  

Mesh:

Year:  2011        PMID: 22117038     DOI: 10.1182/blood-2011-09-378414

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

Review 1.  Brentuximab vedotin.

Authors:  Niels W C J van de Donk; Eugen Dhimolea
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

2.  Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.

Authors:  Andres Forero-Torres; Beata Holkova; Jerome Goldschmidt; Robert Chen; Gregg Olsen; Ralph V Boccia; Rodolfo E Bordoni; Jonathan W Friedberg; Jeff P Sharman; Maria Corinna Palanca-Wessels; Yinghui Wang; Christopher A Yasenchak
Journal:  Blood       Date:  2015-09-16       Impact factor: 22.113

3.  Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma.

Authors:  Alex Reza Gholiha; Peter Hollander; Ingrid Glimelius; Gustaf Hedstrom; Daniel Molin; Henrik Hjalgrim; Karin E Smedby; Jamileh Hashemi; Rose-Marie Amini; Gunilla Enblad
Journal:  Blood Adv       Date:  2021-03-23

Review 4.  Current Treatment Options for Older Patients with Hodgkin Lymphoma.

Authors:  Jordan Carter; Kevin A David; Athena Kritharis; Andrew M Evens
Journal:  Curr Treat Options Oncol       Date:  2020-04-23

5.  Chemotherapy and Radiation Induced Pulmonary Dysfunction in Hodgkin Lymphoma Patients.

Authors:  Sebnem Izmir Guner; Mustafa Teoman Yanmaz; Ahmet Selvi; Cigdem Usul
Journal:  Indian J Hematol Blood Transfus       Date:  2015-11-14       Impact factor: 0.900

6.  Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma.

Authors:  Sameer A Parikh; Thomas M Habermann; Kari G Chaffee; Timothy G Call; Wei Ding; Jose F Leis; William R Macon; Susan M Schwager; Kay M Ristow; Luis F Porrata; Neil E Kay; Susan L Slager; Tait D Shanafelt
Journal:  Am J Hematol       Date:  2015-01-30       Impact factor: 10.047

7.  Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma.

Authors:  Shinichi Makita; Dai Maruyama; Akiko Miyagi Maeshima; Hirokazu Taniguchi; Ken-Ichi Miyamoto; Hideaki Kitahara; Suguru Fukuhara; Wataru Munakata; Yukio Kobayashi; Jun Itami; Kensei Tobinai
Journal:  Int J Hematol       Date:  2016-04-16       Impact factor: 2.490

8.  Continuum of Care for Hodgkin Lymphoma: Impact of Modern Therapy on Postacute Morbidity and Mortality.

Authors:  Andrew M Evens; Susan K Parsons
Journal:  J Clin Oncol       Date:  2020-10-08       Impact factor: 44.544

9.  First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study.

Authors:  Angie Mae Rodday; Theresa Hahn; Anita J Kumar; Peter K Lindenauer; Jonathan W Friedberg; Andrew M Evens; Susan K Parsons
Journal:  Br J Haematol       Date:  2020-02-23       Impact factor: 6.998

10.  The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.

Authors:  Andrew M Evens; Fangxin Hong; Leo I Gordon; Richard I Fisher; Nancy L Bartlett; Joseph M Connors; Randy D Gascoyne; Henry Wagner; Mary Gospodarowicz; Bruce D Cheson; Patrick J Stiff; Ranjana Advani; Thomas P Miller; Richard T Hoppe; Brad S Kahl; Sandra J Horning
Journal:  Br J Haematol       Date:  2013-01-29       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.